Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Terminated 1

Sponsor Class

NIH 2OTHER 1NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Lymphoma 2Leukemia 2Sarcoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Lymphoma, Non-Hodgkin 1Lymphoma, B-Cell, Marginal Zone 1Lung Neoplasms 1Leukemia, Myelomonocytic, Acute 1Leukemia, Myeloid, Acute 1Leukemia, Monocytic, Acute 1Leukemia, Megakaryoblastic, Acute 1Leukemia, Erythroblastic, Acute 1Leukemia, Eosinophilic, Acute 1Leukemia, Basophilic, Acute 1Hematologic Neoplasms 1Desmoplastic Small Round Cell Tumor 1Congenital Abnormalities 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Lobular 1Carcinoma, Intraductal, Noninfiltrating 1Carcinoma, Ductal, Breast 1Breast Neoplasms 1Adenocarcinoma, Bronchiolo-Alveolar 1Adenocarcinoma of Lung 1

Interventions

Carboplatin 34Paclitaxel 29Radiotherapy 23Cisplatin 23Docetaxel 18Pemetrexed 14Gemcitabine 14Radiosurgery 10Bevacizumab 9Magnetic Resonance Spectroscopy 7Etoposide 7Ramucirumab 6Erlotinib Hydrochloride 6Cetuximab 6Specimen Handling 5Gene Expression Profiling 5durvalumab 4cediranib 4Vinorelbine 4Polymerase Chain Reaction 4Amplified Fragment Length Polymorphism Analysis 4pembrolizumab 3cemiplimab 3Watchful Waiting 3Taxes 3Surgical Procedures, Operative 3Radiotherapy, Conformal 3Psychiatric Rehabilitation 3Neoadjuvant Therapy 3Fluorodeoxyglucose F18 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NETWORK × Carcinoma, Non-Small-Cell Lung × Pharmacogenomic Testing × Clear all
NCT01208064 2018-07-12

Pazopanib Hydrochloride or a Placebo in Treating Patients With Non-Small Cell Lung Cancer Who Have Received First-Line Chemotherapy

European Organisation for Research and Treatment of Cancer - EORTC

Phase 2/3 Terminated
102 enrolled
Thoracic

Adenocarcinoma of Lung, Adenocarcinoma, Bronchiolo-Alveolar, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡